Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals reported steady progress in its neurology clinical programs despite COVID-19 disruptions. The company anticipates significant clinical milestones over the next year, including Phase 3 trials for XEN496 in KCNQ2 developmental and epileptic encephalopathy and top-line data from the XEN1101 trial. Financially, as of March 31, 2020, Xenon had $229.7 million in cash, with total revenue of $7.1 million for Q1 2020. The net loss for the quarter was $7.5 million, an improvement from $11.3 million in Q1 2019, reflecting operational efficiency amidst rising clinical development costs.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) plans to report its first quarter 2020 financial and operating results on May 21, 2020, after U.S. markets close. Following this, a conference call and audio webcast will be held at 4:30 PM ET to discuss the results and provide a corporate update. Interested participants can join by dialing (855) 779-9075 or (631) 485-4866 for international callers, using conference ID 8385218. The webcast will be available for replay for 30 days on Xenon's website.